PK007

PK007 is a novel, potent, and orally bioavailable small molecule inhibitor of hematopoietic prostaglandin D2 synthase (HPGDS). It is currently being investigated as a potential therapeutic intervention for Duchenne Muscular Dystrophy (DMD). By inhibiting HPGDS, PK007 reduces the production of Prostaglandin D2 (PGD2), a key mediator that exacerbates muscle damage by enhancing pro-inflammatory chemokine signaling and recruiting immune cells, such as macrophages, to muscle tissue. Preclinical studies in mdx and D2.mdx mouse models have demonstrated that PK007 treatment significantly reduces muscle PGD2 levels, leading to decreased myonecrosis, reduced macrophage infiltration, and improved muscle strength and locomotor activity. Additionally, PK007 has shown promise in improving cardiac function, including increased stroke volume and cardiac output, which are critical factors in managing DMD-associated cardiomyopathy.